Grit Biotechnology
Research - , Shanghai, China
Grit Biotechnology Employees
Grit Biotechnology Details
Grit Bio is a Chinese cell therapy company founded in 2019. The company is developing tumor-infiltrating lymphocyte (TIL) therapy program to address the unmet medical needs and to improve the quality of life for patients with solid tumor. GT101 - Grit's non-gene-modified TIL product manufactured using proprietary process - is the first TIL product received Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trial. Grit Bio has established three core technology platforms for its TIL development: StaViral® - a retroviral system tailored for TIL engineering, ImmuT Finder® - a high-throughput screening platforms identifying novel T-cell targets, and TIL expansion platform StemTexp® that preferentially enriches TCM and TSCM populations of TIL. The company is currently developing potentially best-in-class gene-engineered TIL therapy based on these platforms.
Grit Biotechnology Technologies
Content Syndication Networks
Content.ad
Frameworks and Programming Languages
ASP.NET
Other
Mobile Friendly